Fieldview Capital Management LLC Acquires Shares of 6,812 Masimo Corporation $MASI

Fieldview Capital Management LLC acquired a new position in shares of Masimo Corporation (NASDAQ:MASI) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 6,812 shares of the medical equipment provider’s stock, valued at approximately $1,005,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in MASI. Royal Bank of Canada grew its stake in Masimo by 44.5% during the 1st quarter. Royal Bank of Canada now owns 43,884 shares of the medical equipment provider’s stock worth $7,311,000 after buying an additional 13,513 shares during the last quarter. AQR Capital Management LLC lifted its stake in Masimo by 136.5% in the first quarter. AQR Capital Management LLC now owns 8,142 shares of the medical equipment provider’s stock valued at $1,305,000 after buying an additional 4,700 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Masimo by 0.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider’s stock valued at $1,894,000 after buying an additional 66 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Masimo in the first quarter valued at approximately $220,000. Finally, Jones Financial Companies Lllp boosted its holdings in shares of Masimo by 1,267.1% in the first quarter. Jones Financial Companies Lllp now owns 2,201 shares of the medical equipment provider’s stock valued at $367,000 after acquiring an additional 2,040 shares during the period. Institutional investors and hedge funds own 85.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Masimo in a report on Thursday, January 22nd. Wolfe Research cut shares of Masimo from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 19th. BTIG Research downgraded shares of Masimo from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 18th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research note on Monday, December 1st. Finally, Wells Fargo & Company cut shares of Masimo from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $190.00 to $180.00 in a report on Wednesday, February 18th. One research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $181.17.

Masimo Price Performance

Masimo stock opened at $175.45 on Tuesday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.49 and a quick ratio of 1.47. The business has a 50 day simple moving average of $148.13 and a 200-day simple moving average of $145.04. Masimo Corporation has a 12 month low of $125.94 and a 12 month high of $175.90. The stock has a market capitalization of $9.42 billion, a PE ratio of -16.65, a price-to-earnings-growth ratio of 1.78 and a beta of 1.21.

Masimo Company Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.